Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, +11 more
Nature (2014)
Antisense knockdown of nicotinamide N-methyltransferase in white adipose tissue and liver of diet-induced-obese mice protected against weight gain, improved insulin sensitivity, and elevated tissue SAM and NAD+ levels — without changes in food intake. The mechanistic anchor for every subsequent 5-Amino-1MQ paper.
This is the foundational Nature paper that proposed nicotinamide N-methyltransferase (NNMT) as a therapeutic target in diet-induced obesity, published in 2014 by Kraus, Yang, and colleagues in Barbara Kahn's laboratory at Beth Israel Deaconess Medical Center (Harvard Medical School), with collaborating contributions from groups at multiple institutions. The paper uses an antisense-oligonucleotide approach to selectively knock down NNMT expression in white adipose tissue and liver of mice on a high-fat diet, and reports a coherent metabolic phenotype: protection against diet-induced obesity, improved insulin sensitivity and glucose tolerance, smaller adipocyte size, and a tissue-metabolite signature characterized by elevated S-adenosylmethionine (SAM) and elevated nicotinamide adenine dinucleotide (NAD+) levels.
The mechanism proposed in the paper routes through polyamine flux and cellular energy expenditure. NNMT methylates nicotinamide using SAM as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. The enzyme therefore sits at a metabolic crossroads where two regulatory systems converge: the NAD+ salvage pathway (because nicotinamide is the NAD+ precursor that NNMT diverts toward methylation and excretion) and the SAM cycle (because every NNMT turnover consumes one SAM molecule). NNMT knockdown elevates both SAM and NAD+ in the adipose-tissue context and upregulates the polyamine-metabolism enzymes ornithine decarboxylase (ODC), spermidine/spermine-N¹-acetyltransferase (SSAT), and polyamine oxidase (PAO), driving a futile polyamine-cycle phenotype that increases cellular energy expenditure. Critically, the obesity-protection effect occurs without changes in food intake — implicating altered energy partitioning rather than appetite suppression as the metabolic mechanism, which is the framing that distinguishes the NNMT target from the broader incretin-class anti-obesity pharmacology.
The paper proposed NNMT as a therapeutic target rather than as a small-molecule program in its own right; the pharmacological replication of the antisense-knockdown phenotype was developed subsequently by other groups, most notably the Neelakantan et al. 2018 paper that introduced 5-amino-1-methylquinolinium (5-Amino-1MQ) as a selective small-molecule NNMT inhibitor and demonstrated that systemic small-molecule inhibition reproduces the core metabolic phenotype the Kraus genetic approach established. The 2014 paper is the mechanistic foundation that the entire 5-Amino-1MQ peptide page rests on; without it, the molecule would not have a target rationale.
The paper is preclinical and rodent-only — no human data. Antisense-oligonucleotide knockdown is a powerful target-validation tool, but it produces a stronger and more durable suppression of target enzyme activity than any pharmacological small-molecule inhibitor in clinical use is likely to achieve at tolerated chronic exposure; the translational gap between an antisense-knockdown phenotype and a small-molecule-inhibition phenotype is meaningful and is part of why the Neelakantan 2018 pharmacological replication mattered for the field. The model is diet-induced obesity in C57BL/6 mice, which is the conventional mouse obesity model but is not a perfect proxy for human obesity in its genetics, metabolic-flux distribution, or therapeutic-response patterns. The SAM-elevation phenotype is reported as beneficial in this context, but SAM is the methyl donor for every cellular methyltransferase including the DNA methyltransferases that maintain CpG methylation patterns and the histone methyltransferases that maintain chromatin state — and the chronic-exposure consequences of sustained SAM elevation in a non-disease context are not characterized in this paper or in any subsequent published study of long-duration NNMT inhibition. The conclusions extend to the adipose-tissue and hepatic-tissue context where the knockdown was targeted; whether the metabolic phenotype generalizes to skeletal muscle, cardiac tissue, or central nervous system tissue with chronic systemic NNMT inhibition is the question that subsequent papers (Neelakantan 2019 muscle-stem-cell work, Dimet-Wiley 2022 microbiome work) have begun to address but have not closed. Sponsorship and conflict disclosures are documented in the paper. No human trial of any NNMT inhibitor has been completed as of 2026 — the gray-market use of 5-Amino-1MQ described on the /peptides/5-amino-1mq page rests on the mechanistic logic of this paper plus its small-molecule successor, not on any direct human evidence.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.